论文部分内容阅读
Objective:To analyze Fms-like tyrosine kinase 3(FLT3)/internal-tandem duplications(ITD)mutations in various kinds of hematologic malignancy patients.Methods:FLT3/ITD gene mutations were detected by polymerase chain reaction(PCR)in 103 acute myeloid leukemia(AML)cases,63 acute lymphocytic leukemia(ALL)cases,53 chronic myelogenous leu-kemia(CML)cases in chronic phase(CML-CP),34 CML cases in blast crisis(CML-BC),11 chronic lymphatic leukemia(CLL)cases,36 myelodysplastic syndrome(MDS)cases,9 multiple myeloma(MM)cases and 13 non-hodgkin’s lymphoma(NHL)cases with marrow infiltration.Results:The expressions of FLT3/ITD gene mutations were detected in 22.3% AML cases,in 6.5% CML-BC cases,in 5.6% MDS cases and in 2.6% ALL cases.The two ALL cases with FLT3/ITD mutation were diagnosed as ALL-L2 with morphology and both with myeloid antigen expression,but finally were diagnosed as acute mixed-lineage leukemia after immunology examination.FLT3/ITD gene mutations were not detected in CML-CP,MM,NHL and CLL cases.In the 23 AML patients with FLT3/ITD gene mutation,including 2 of 8 M1(2.5%),8 of 33 M2(24.2%),7 of 24 M3(29.3%),2 of 11 M4(18.2%),3 of 21 M5(14.3%),1 of 5 M6(20%),and 0 of 1 M7 cases,and there were no significant differences in the positive rates of FLT3/ITD mutations between the FAB subtypes(P > 0.05).Statistical analyses showed that in AML patients,FLT3/ITD was associated with a higher peripheral blood white cell(WBC)counts [(41.23 ± 32.56)× 109 /L vs(11.36 ± 9.89)× 109 /L(P < 0.01)],higher percentage of bone marrow blast cells [(72.78 ± 21.79)% vs(51.26 ± 20.78)%(P < 0.05)],and higher cumulative relapse rates(63.6% vs 27.7%,P < 0.025)than those negative.Conclusion:FLT3/ITD gene mutation mainly oc-curred in AML patients,and might be a strong prognostic factor which was associated with high peripheral WBC counts,bone marrow blast cell proportion and a increased relapse risk in AML.Detection of FLT3/ITD gene mutation might provide insights to explore a more accurate genotyping of leukemia,differential diagnosis between AML and ALL,subdivide risk level in AML and estimate prognosis of leukemia.
Objective: To analyze Fms-like tyrosine kinase 3 (FLT3) / internal-tandem duplications (ITD) mutations in various kinds of hematologic malignancy patients. Methods: FLT3 / ITD gene mutations were detected by polymerase chain reaction (PCR) in 103 acute myeloid Fifty-three cases of chronic myelogenous leukemia (CML) cases in chronic phase (CML-CP), 34 CML cases in blast crisis (CML-BC), 11 chronic lymphatic leukemia (CLL) cases, 36 myelodysplastic syndrome (MDS) cases, 9 multiple myeloma (MM) cases and 13 non-hodgkin’s lymphoma (NHL) cases with marrow infiltration. Results: The expressions of FLT3 / ITD gene mutations were detected in 22.3% AML cases, in 6.5% CML-BC cases, in 5.6% of MDS cases and in 2.6% of ALL cases with two ALL cases with FLT3 / ITD mutation were diagnosed as ALL-L2 with morphology and both with myeloid antigen expression, but finally were diagnosed as acute mixed-lineage leukemia after immunology examination. FLT3 / ITD gene mutations were not detected in CML-CP, MM, NHL a nd CLL cases in the 23 AML patients with FLT3 / ITD gene mutation, including 2 of 8 M1 (2.5%), 8 of 33 M2 (24.2%), 7 of 24 M3 (29.3%), 2 of 11 M4 3 of 21 M5 (14.3%), 1 of 5 M6 (20%), and 0 of 1 M7 cases, and there were no significant differences in the positive rates of FLT3 / ITD mutations between the FAB subtypes (P> 0.05). Statistical analysis showed that in AML patients FLT3 / ITD was associated with a higher peripheral blood white cell (WBC) counts [(41.23 ± 32.56) × 109 / L vs (11.36 ± 9.89 × 109 / L, P < 0.01), higher percentage of bone marrow blast cells [(72.78 ± 21.79)% vs (51.26 ± 20.78)% (P <0.05)], and higher cumulative relapse rates (63.6% vs 27.7%, P <0.025) negative.Conclusion: FLT3 / ITD gene mutation mainly oc-curred in AML patients, and might be a strong prognostic factor which was associated with high peripheral WBC counts, bone marrow blast cell proportion and a increased relapse risk in AML. Detection of FLT3 / ITD gene mutation might provide insights to explore a more accurate genottyping of leukemia, differential diagnosis between AML and ALL, subdivide risk level in AML and estimate prognosis of leukemia.